There were 429 press releases posted in the last 24 hours and 457,089 in the last 365 days.

Progenics Pharmaceuticals Announces Presentations on AZEDRA® (iobenguane I 131) and its Prostate Cancer Programs at the 30th Annual Congress of the European Association of Nuclear Medicine

/EIN News/ -- NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that data from several of the Company’s development programs will be presented in oral sessions at the 30th Annual Congress of the European Association of Nuclear Medicine (EANM), which is being held in Vienna, Austria from October 21 through 25, 2017.

Presentation details are as follows:
Date & Time: Sunday, October 22, 2017, 2:30 PM - 4:00 PM local time
Session Title: 407 - Clinical Oncology - Rapid Fire Session: Prostate
Session Type: Oral Abstract Presentation OP-119, OP-127
Title: “Tc-99-MIP-1404 Imaging for the Detection of PSMA-Positive Lesions. A Pilot Study in 380 Patients with Histologically Confirmed Prostate Cancer”
Title: “First Clinical Experience with Ultra-High Resolution Multi-Focal Collimators for Tc-99m- PSMA Imaging”

Date & Time: Sunday, October 22, 2017, 4:30 PM - 6:00 PM local time
Session Title: 507 - Clinical Oncology: NET, a Classic!
Session Type: Oral Abstract Presentation
Title: “AZEDRA® (iobenguane I 131) in Patients with Malignant and/or Recurrent Pheochromocytoma/ Paraganglioma (PPGL): Overall Tumor Response Assessment”

Date & Time: Wednesday, October 25, 2017, 8:00 AM – 9:30 AM local time
Session Title: 1607 – Clinical Oncology: Anything Goes
Session Type: Oral Abstract Presentation
Title: “Convolutional neural networks for segmentation of 49 selected bones in CT images show high reproducibility”

About Progenics
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.

This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward-looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as the Phase 3 clinical program for 1404; our ability to successfully develop and commercialize the products of EXINI Diagnostics AB; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs, including our NDA for AZEDRA; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company's SEC filings.



Melissa Downs
Investor Relations
(646) 975-2533

Primary Logo